Remifentanil intravenous patient controlled analgesia (PCA) versus intramuscular Pethidine for pain relief in labour.
THE MAIN TRIAL FEATURES:
- A randomised controlled trial.
- Funded by the National Institute for Health Research (NIHR).
- Run by Matthew Wilson (Chief Investigator).
- Taking place primarily at Birmingham Women's Hospital in the West Midlands, but will be roled out to centres nationwide.
- Birmingham Clinical Trials Unit at the University of Birmingham will be overseeing the administrative side of the Trial.
- It is hoped that 400 patients will be recruited over a 20 month period beginning in March 2014.
- Participating women will be randomly allocated either Pethidine injection OR Remifentanil patient controlled analgesia pain relief during labour.
- The primary outcome will be the proportion of women, in each arm, that go on to need epidural analgesia.
- Patients will receive Maternal Satisfaction questionnaires to complete during their admission, but will not need to be followed up after discharge.
- The Trial is designed to fit in with routine hospital practice as far as possible.
For the latest Patient Information Leaflet click here
For a list of frequently asked questions click here
Tweets by @RESPITE_Trial